Tuesday, March 31, 2026 – TUESDAY, March 31, 2026 -- For adults with type 2 diabetes, discontinuation of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with an increased risk for major adverse cardiovascular events, according to a study published online...
Tuesday, March 31, 2026 – Wednesday, April 1 - (MedPage Today) -- The PREVENT-TAHA8 intracoronary stem cell trial from Iran was officially retracted by The BMJ, months after an expression of concern was first published.
Poor diet remains a leading contributor to ischemic heart disease, with...
Tuesday, March 31, 2026 – Wednesday, April 1 - (MedPage Today) -- A 6-month hiatus in GLP-1 drug use was linked with an increased risk of major adverse cardiovascular events in patients with type 2 diabetes compared with continued use, according to a target trial emulation. (BMJ Medicine)...
Tuesday, March 31, 2026 – Wednesday, April 1 - A nascent biotech in the suburbs of Denver has convinced investors to commit $100 million to develop an oral small molecule in one of the most competitive fields in drug development.
Ambrosia Biosciences snagged the ...
Tuesday, March 31, 2026 – Wednesday, April 1 - Novo Nordisk is unveiling a subscription model for self-pay customers of its popular GLP-1 weight loss drug Wegovy with much lower prices for both the injectable and the pill through three telehealth services. It’s the latest effort by drug makers to reduce prices which includes partnering with big box stores to entice more patients. NBC’s Anne Thompson reports for TODAY.
Tuesday, March 31, 2026 – Tuesday, March 31 - You can now pay for Wegovy shots and pills just like you pay for an Amazon Prime subscription.
Novo Nordisk said patients paying cash can opt for 3-month, 6-month and yearlong subscriptions, securing a lower ...
Monday, March 30, 2026 – Tuesday, March 31 - (MedPage Today) -- DENVER -- Adding a GLP-1 agonist to psoriasis medication significantly improved outcomes in patients with psoriatic arthritis (PsA) and overweight or obesity, a phase III randomized trial showed.
After 36 weeks, almost a third...
Monday, March 30, 2026 – Tuesday, March 31 - An analysis of patient-reported outcomes (PROs) from the SURPASS-SWITCH trial found that adults with type 2 diabetes who switched from dulaglutide to tirzepatide not only saw stronger improvements in blood sugar and weight but also reported feeling emotionally better.
Monday, March 30, 2026 – Tuesday, March 31 - Researchers at the Institute for Bioengineering of Catalonia (IBEC) have produced a mutational map showing how mutations in amylin—a hormone that plays a key role in glucose regulation—affect its tendency to form toxic amyloid aggregates in the pancreas. This process is linked to the development of type 2 diabetes. While it was already known that certain mutations could alter this aggregation capacity, understanding of this process was fragmented and based on isolated studies. The research is published in the journal Nature Communications.
Monday, March 30, 2026 – Monday, March 30 - Accumulating scientific evidence and industry interest from Eli Lilly, Altimmune and startup Baseline Therapeutics is driving further research on the therapeutic potential of GLP-1 receptor agonists in treating substance use disorders.